CARE

CARTER BANKSHARES INC

Financial Services | Small Cap

$0.58

EPS Forecast

$49.34

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Carter Bankshares, CARE: A Careful Quarter of One‑Time Gains and Strategic Pivoting in Q3 2026

Ticker CARE on NASDAQ faced a quarter where nonrecurring items hog the spotlight, while core earnings and loan growth hint at a path forward. In this report, we dissect the numbers (EPS, net income, net interest income) and what they might mean for CARE and its peers in a rate‑sensitive banking landscape.

Earnings snapshot: CARE delivers Q3 2026 with a mix of one‑offs and ongoing momentum

The company reported a third‑quarter 2026 net income of $7.8 million, or $0.35 per diluted share (EPS). This sits against the backdrop of a prior quarter’s standalone earnings and a YoY comparison featuring a far smaller base in 2025. For the nine months ended September 30, 2026, net income was $122.4 million, or $5.53 per diluted share, versus $22.9 million and $1.00 per share for the same period in 2025. Net interest income meanwhile stood at $41.2 million for Q3 2026, up modestly for the quarter but supported by a broader balance‑sheet repositioning story.

The company flagged an Adjusted net income of $7.6 million for the third quarter of 2026, illustrating the interplay between recurring earnings and nonrecurring items that flow through the books. Management also noted adjusted figures for the nine months ended September 30, 2026 of $27.8 million, versus $22.3 million in the prior year period. In other words: core earnings are visible, but a chunk of the quarterly narrative rests on nonrecurring pre‑tax gains tied to strategic actions earlier in the year.

Important context for investors: CARE does not publish a formal EPS consensus in the press release, so readers should view the reported EPS in light of the absence of an explicit earnings surprise figure from Street estimates in this filing. The absence of a stated EPS consensus means the headline result is not framed as a beat or miss against a published target, but rather as a reflection of the quarter’s mix of operating performance and one‑time adjustments. On the top line, there is no formal revenue forecast presented in the release, leaving investors to extrapolate from the loan growth and net interest income trajectories described by management.

What happened this quarter: the levers CARE pulled

  • Strategic transactions: In the first half of 2026, CARE completed two notable transactions—the sale of a large nonperforming credit relationship (the Loan Sale Transaction) and the sale of its membership interest in Bearing Insurance Group, LLC (the Insurance Transaction). These moves generated aggregate nonrecurring pre‑tax gains of roughly $100.9 million in the first six months of 2026, providing a liquidity and balance‑sheet boost that supports a more flexible earnings base going forward.
  • Portfolio repositioning: As part of the strategic repositioning, CARE executed a portfolio repositioning in the second quarter of 2026, recognizing a pre‑tax loss of $12.5 million. The sale of $139.4 million in book value of lower‑yielding securities and the purchase of about $88.5 million of higher‑yielding securities aimed to strengthen interest income and liquidity for organic loan growth, even as it produced near‑term headwinds.
  • Revenue and loan‑growth dynamics: For the three months ended September 30, 2026, total portfolio loans rose by $36.0 million from June 30, 2026, even as approximately $161.0 million in loan payoffs occurred in the quarter. Relative to September 30, 2025, loans were down 1.7% on a reported basis, but up 4.53% when excluding the impact of the Loan Sale Transaction in Q1 2026. Net interest income was $41.2 million for Q3 2026, up modestly versus the prior quarter and up meaningfully versus the prior year quarter.
  • Balance‑sheet discipline and growth runway: The company has moved to diversify and strengthen its balance sheet via DRIP (Dividend Reinvestment and Stock Purchase Plan) enrollment for up to 1.0 million shares, alongside a dedicated SBA lending team that started in Q3 2026 to broaden financing solutions for small businesses nationwide.

Implications for CARE and sector peers

What the quarter signals is a company consciously balancing recurring earnings with strategic actions intended to improve long‑term earnings potential. The near‑term driver of earnings power appears to be a combination of nonrecurring gains from legacy asset dispositions and ongoing improvements in net interest income, aided by a higher net interest margin—3.51% in Q3 2026, up from the prior quarter and well above YoY levels. The margin expansion—up 65 basis points versus the year‑ago quarter—suggests CARE benefited from balance‑sheet repositioning in a rate environment where yield differentials matter as much as credit costs.

For CARE’s sector peers, the narrative reinforces a broader theme: opportunistic asset sales and portfolio restructuring can broaden the earnings toolkit, but investors will scrutinize the durability of core earnings when a substantial portion of quarterly profitability hinges on one‑time items. The presence of a DRIP and a focused SBA lending initiative hints at a plan to compound earnings by growing deposits and expanding fee and interest income through targeted lending segments, not merely relying on interest‑rate swings.

Analysts and investors will likely watch how the company sustains loan production and whether the improved NIM can be maintained as balance sheets continue to rebalance in response to macro shifts. In practice, CARE’s approach could become a blueprint for banks navigating the tension between capital return, liquidity management, and the need to build a robust core earnings stream that doesn’t depend solely on disposition gains.

Key numbers at a glance

  • Ticker: CARE; Exchange: NASDAQ
  • Q3 2026 net income: $7.8 million; EPS: $0.35
  • Q3 2026 adjusted net income: $7.6 million
  • Nine months ended Sept 30, 2026 net income: $122.4 million; diluted EPS: $5.53
  • Net interest income (Q3 2026): $41.2 million
  • Net interest margin (NIM, Q3 2026): 3.51% (up from 3.38% in the prior quarter; up 65 bps YoY)
  • Total portfolio loans: up $36.0 million sequentially; $161.0 million in loan payoffs during Q3
  • Ex‑Loan Sale impact: excluding the Loan Sale Transaction, loan growth would be up about 4.53% YoY
  • Strategic actions: $100.9 million of aggregate pre‑tax gains from early‑year transactions; $12.5 million pre‑tax loss from portfolio repositioning
  • DRIP: up to 1.0 million shares offered to existing shareholders
  • SBA lending team: launched to broaden nationwide small business financing
  • Revenue forecast: no formal forecast provided in the release; investors will extrapolate from loan growth and NIM trajectory
  • EPS consensus: not disclosed in the filing; no explicit earnings surprise reported

Bottom line: CARE’s quarter reads as a transition story

The Q3 2026 results underscore a deliberate strategy: monetize certain assets for nonrecurring gains, sharpen the balance sheet, and pursue growth through smarter lending and equity tools like a DRIP. The absence of a disclosed EPS consensus means the market will grade CARE on durability rather than a one‑off beat, at least until guidance or channel checks provide a clearer directional signal. For sector peers, the mix of nonrecurring gains, yield management, and growth initiatives could be a template—applied selectively—as banks navigate higher rates, asset quality concerns, and the need to fund organic loan growth with liquidity that remains reasonably priced.

In short, CARE’s Q3 shows a bank that has not abandoned earnings growth, but reengineered the engine. The question now is whether the core earnings power—driven by net interest income and asset sensitivity—can sustain a multi‑quarter rhythm or if the next few quarters will resemble a continuation of the balancing act on display in this report.

Disclaimer: This analysis synthesizes the disclosed data from Carter Bankshares, Inc. press materials and expects readers to consult official filings for complete details. Ticker CARE, EPS figures, and references to earnings surprises, EPS consensus, and revenue forecasts appear in alignment with standard financial reporting terminology.